112 related articles for article (PubMed ID: 38055801)
1. Genomic instability analysis in DNA from Papanicolaou test provides proof-of-principle early diagnosis of high-grade serous ovarian cancer.
Paracchini L; Mannarino L; Romualdi C; Zadro R; Beltrame L; Fuso Nerini I; Zola P; Laudani ME; Pagano E; Giordano L; Fruscio R; Landoni F; Franceschi S; Dalessandro ML; Canzonieri V; Bocciolone L; Lorusso D; Bosetti C; Raspagliesi F; Garassino IMG; ; D'Incalci M; Marchini S
Sci Transl Med; 2023 Dec; 15(725):eadi2556. PubMed ID: 38055801
[TBL] [Abstract][Full Text] [Related]
2. Detection of TP53 Clonal Variants in Papanicolaou Test Samples Collected up to 6 Years Prior to High-Grade Serous Epithelial Ovarian Cancer Diagnosis.
Paracchini L; Pesenti C; Delle Marchette M; Beltrame L; Bianchi T; Grassi T; Buda A; Landoni F; Ceppi L; Bosetti C; Paderno M; Adorni M; Vicini D; Perego P; Leone BE; D'Incalci M; Marchini S; Fruscio R
JAMA Netw Open; 2020 Jul; 3(7):e207566. PubMed ID: 32609349
[TBL] [Abstract][Full Text] [Related]
3. Abnormal plasma DNA profiles in early ovarian cancer using a non-invasive prenatal testing platform: implications for cancer screening.
Cohen PA; Flowers N; Tong S; Hannan N; Pertile MD; Hui L
BMC Med; 2016 Aug; 14(1):126. PubMed ID: 27558279
[TBL] [Abstract][Full Text] [Related]
4. Detecting TP53 mutations in diagnostic and archival liquid-based Pap samples from ovarian cancer patients using an ultra-sensitive ddPCR method.
Arildsen NS; Martin de la Fuente L; Måsbäck A; Malander S; Forslund O; Kannisto P; Hedenfalk I
Sci Rep; 2019 Oct; 9(1):15506. PubMed ID: 31664085
[TBL] [Abstract][Full Text] [Related]
5. Molecular Management of High-Grade Serous Ovarian Carcinoma.
Punzón-Jiménez P; Lago V; Domingo S; Simón C; Mas A
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430255
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of liquid from the Papanicolaou test and other liquid biopsies for the detection of endometrial and ovarian cancers.
Wang Y; Li L; Douville C; Cohen JD; Yen TT; Kinde I; Sundfelt K; Kjær SK; Hruban RH; Shih IM; Wang TL; Kurman RJ; Springer S; Ptak J; Popoli M; Schaefer J; Silliman N; Dobbyn L; Tanner EJ; Angarita A; Lycke M; Jochumsen K; Afsari B; Danilova L; Levine DA; Jardon K; Zeng X; Arseneau J; Fu L; Diaz LA; Karchin R; Tomasetti C; Kinzler KW; Vogelstein B; Fader AN; Gilbert L; Papadopoulos N
Sci Transl Med; 2018 Mar; 10(433):. PubMed ID: 29563323
[TBL] [Abstract][Full Text] [Related]
7. Characterization of TP53 mutations in Pap test DNA of women with and without serous ovarian carcinoma.
Krimmel-Morrison JD; Ghezelayagh TS; Lian S; Zhang Y; Fredrickson J; Nachmanson D; Baker KT; Radke MR; Hun E; Norquist BM; Emond MJ; Swisher EM; Risques RA
Gynecol Oncol; 2020 Feb; 156(2):407-414. PubMed ID: 31839337
[TBL] [Abstract][Full Text] [Related]
8. High-grade serous ovarian carcinoma organoids as models of chromosomal instability.
Vias M; Morrill Gavarró L; Sauer CM; Sanders DA; Piskorz AM; Couturier DL; Ballereau S; Hernando B; Schneider MP; Hall J; Correia-Martins F; Markowetz F; Macintyre G; Brenton JD
Elife; 2023 May; 12():. PubMed ID: 37166279
[TBL] [Abstract][Full Text] [Related]
9. Prospects of Improving Early Ovarian Cancer Diagnosis Using Cervical Cell Swabs.
Biskup E; Wils RS; Hogdall C; Hogdall E
Anticancer Res; 2022 Jan; 42(1):1-12. PubMed ID: 34969703
[TBL] [Abstract][Full Text] [Related]
10. Studying platinum sensitivity and resistance in high-grade serous ovarian cancer: Different models for different questions.
Alkema NG; Wisman GB; van der Zee AG; van Vugt MA; de Jong S
Drug Resist Updat; 2016 Jan; 24():55-69. PubMed ID: 26830315
[TBL] [Abstract][Full Text] [Related]
11. Tumor specific methylome in Chinese high-grade serous ovarian cancer characterized by gene expression profile and tumor genotype.
Song F; Li L; Zhang B; Zhao Y; Zheng H; Yang M; Li X; Tian J; Huang C; Liu L; Wang Q; Zhang W; Chen K
Gynecol Oncol; 2020 Jul; 158(1):178-187. PubMed ID: 32362568
[TBL] [Abstract][Full Text] [Related]
12. Methylome analysis of extreme chemoresponsive patients identifies novel markers of platinum sensitivity in high-grade serous ovarian cancer.
Tomar T; Alkema NG; Schreuder L; Meersma GJ; de Meyer T; van Criekinge W; Klip HG; Fiegl H; van Nieuwenhuysen E; Vergote I; Widschwendter M; Schuuring E; van der Zee AGJ; de Jong S; Wisman GBA
BMC Med; 2017 Jun; 15(1):116. PubMed ID: 28641578
[TBL] [Abstract][Full Text] [Related]
13. Chromosome instability is prevalent and dynamic in high-grade serous ovarian cancer patient samples.
Morden CR; Farrell AC; Sliwowski M; Lichtensztejn Z; Altman AD; Nachtigal MW; McManus KJ
Gynecol Oncol; 2021 Jun; 161(3):769-778. PubMed ID: 33714608
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of paraneoplastic antigens reveals TRIM21 autoantibodies as biomarker for early detection of ovarian cancer in combination with autoantibodies to NY-ESO-1 and TP53.
Hurley LC; Levin NK; Chatterjee M; Coles J; Muszkat S; Howarth Z; Dyson G; Tainsky MA
Cancer Biomark; 2020; 27(3):407-421. PubMed ID: 32083570
[TBL] [Abstract][Full Text] [Related]
15. Prospective study of the efficacy and utility of TP53 mutations in circulating tumor DNA as a non-invasive biomarker of treatment response monitoring in patients with high-grade serous ovarian carcinoma.
Kim YM; Lee SW; Lee YJ; Lee HY; Lee JE; Choi EK
J Gynecol Oncol; 2019 May; 30(3):e32. PubMed ID: 30887755
[TBL] [Abstract][Full Text] [Related]
16. Somatic Mutational Profile of High-Grade Serous Ovarian Carcinoma and Triple-Negative Breast Carcinoma in Young and Elderly Patients: Similarities and Divergences.
Serio PAMP; de Lima Pereira GF; Katayama MLH; Roela RA; Maistro S; Folgueira MAAK
Cells; 2021 Dec; 10(12):. PubMed ID: 34944094
[TBL] [Abstract][Full Text] [Related]
17. Classification of High-Grade Serous Ovarian Carcinoma by Epithelial-to-Mesenchymal Transition Signature and Homologous Recombination Repair Genes.
Sohn MH; Kim SI; Shin JY; Kim HS; Chung HH; Kim JW; Lee M; Seo JS
Genes (Basel); 2021 Jul; 12(7):. PubMed ID: 34356119
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of DNA from the Papanicolaou test to detect ovarian and endometrial cancers.
Kinde I; Bettegowda C; Wang Y; Wu J; Agrawal N; Shih IeM; Kurman R; Dao F; Levine DA; Giuntoli R; Roden R; Eshleman JR; Carvalho JP; Marie SK; Papadopoulos N; Kinzler KW; Vogelstein B; Diaz LA
Sci Transl Med; 2013 Jan; 5(167):167ra4. PubMed ID: 23303603
[TBL] [Abstract][Full Text] [Related]
19. Exosomal miR-1290 is a potential biomarker of high-grade serous ovarian carcinoma and can discriminate patients from those with malignancies of other histological types.
Kobayashi M; Sawada K; Nakamura K; Yoshimura A; Miyamoto M; Shimizu A; Ishida K; Nakatsuka E; Kodama M; Hashimoto K; Mabuchi S; Kimura T
J Ovarian Res; 2018 Sep; 11(1):81. PubMed ID: 30219071
[TBL] [Abstract][Full Text] [Related]
20. DNA Methylation Profiling of Premalignant Lesions as a Path to Ovarian Cancer Early Detection.
Ishak CA; De Carvalho DD
Clin Cancer Res; 2020 Dec; 26(23):6083-6085. PubMed ID: 32988966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]